An overview of new antitubercular drugs, drug candidates, and their targets
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
The causative agent of tuberculosis (TB), Mycobacterium tuberculosis and more recently totally drug‐resistant strains of M. tuberculosis, display unique mechanisms to survive in the host. A four‐drug treatment regimen was introduced 40 years ago but the emergence of multidrug‐resistance and more recently TDR necessitates the identification of new targets and drugs for the cure of M. tuberculosis infection. The current efforts in the drug development process are insufficient to completely eradicate the TB epidemic. For almost five decades the TB drug development process remained stagnant. The last 10 years have made sudden progress giving some new and highly promising drugs including bedaquiline, delamanid, and pretomanid. Many of the candidates are repurposed compounds, which were developed to treat other infections but later, exhibited anti‐TB properties also. Each class of drug has a specific target and a definite mode of action. These targets are either involved in cell wall biosynthesis, protein synthesis, DNA/RNA synthesis, or metabolism. This review discusses recent progress in the discovery of newly developed and Food and Drug Administration approved drugs as well as repurposed drugs, their targets, mode of action, drug‐target interactions, and their structure‐activity relationship.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis
Andries, K., Verhasselt, P., Guillemont, J., Göhlmann, H. W. H., Neefs, J.-M., Winkler, H., Van Gestel, J., Timmerman, P., Zhu, M., Lee, E., et al. (2005) · Science · doi:10.1126/science.1106753 · Cited by 2,191 · cited 1×
“Bedaquiline blocks these ion‐binding sites thereby interfering with the proton pump which results in decreased intracellular ATP levels.(25,30) A recent study suggested that in addition to the c subunit, bedaquiline also targets the ε subunit of F‐ATP synthase by interacting with Trp16 residue.”
BackgroundPai, M., Behr, M. A., Dowdy, D., Dheda, K., Divangahi, M., Boehme, C. C., Ginsberg, A., Swaminathan, S., Spigelman, M., Getahun, H., et al. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.76 · Cited by 1,270
Identification of nitric oxide synthase as a protective locus against tuberculosis
MacMicking, J. D., North, R. J., LaCourse, R., Mudgett, J. S., Shah, S. K., & Nathan, C. F. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.10.5243 · Cited by 1,180 · cited 1×
“The inhibitory action of delamanid probably involves the release of reactive radicals like NO which are crucial in mammalian defense mechanism against mycobacterial infections.(2,58,59) The exact target of delamanid is yet to be explored.”
BackgroundRibosome-targeting antibiotics and mechanisms of bacterial resistance
Wilson, D. N. (2014) · Nature Reviews Microbiology · doi:10.1038/nrmicro3155 · Cited by 1,054 · cited 2×
“Each subunit is made up of ribosomal RNA (rRNA) and many proteins (rproteins) that work together to synthesize proteins for the cell.(87,88) At present streptomycin,”
BackgroundBenzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis
Makarov, V., Manina, G., Mikusova, K., Möllmann, U., Ryabova, O., Saint-Joanis, B., Dhar, N., Pasca, M. R., Buroni, S., Lucarelli, A. P., et al. (2009) · Science · doi:10.1126/science.1171583 · Cited by 740 · cited 2×
“A nitro group at position 8 is also necessary for antimycobacterial activity.(198) Hydrophilic groups BAHUGUNA AND RAWAT | 281”
BackgroundThe ATP synthase: the understood, the uncertain and the unknown
Walker, J. E. (2013) · Biochemical Society Transactions · doi:10.1042/bst20110773 · Cited by 614
Diarylquinolines target subunit c of mycobacterial ATP synthase
Koul, A., Dendouga, N., Vergauwen, K., Molenberghs, B., Vranckx, L., Willebrords, R., Ristic, Z., Lill, H., Dorange, I., Guillemont, J., et al. (2007) · Nature Chemical Biology · doi:10.1038/nchembio884 · Cited by 547
Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane
Grzegorzewicz, A. E., Pham, H., Gundi, V. A. K. B., Scherman, M. S., North, E. J., Hess, T., Jones, V., Gruppo, V., Born, S. E. M., Korduláková, J., et al. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.794 · Cited by 442 · cited 2×
“tuberculosis involved in cell wall synthesis.(185,186) The structural design of SQ109 originated from ethambutol, an established first‐line drug for the treatment of TB.”
BackgroundOutpatient gatifloxacin therapy and dysglycemia in older adults.
Park-Wyllie, L. Y., Juurlink, D. N., Kopp, A., Shah, B. R., Stukel, T. A., Stumpo, C., Dresser, L., Low, D. E., & Mamdani, M. M. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055191 · Cited by 367 · cited 1×
“compounds like gatifloxacin causes hyperglycemia/hypoglycemia whereas moxifloxacin shows cardiovascular risks.(15,121,122) Moxifloxacin holds the potential of becoming first‐line anti‐TB agent and is under phase III clinical trial.”
BackgroundUnique Flexibility in Energy Metabolism Allows Mycobacteria to Combat Starvation and Hypoxia
Berney, M., & Cook, G. M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008614 · Cited by 235
Energetics of Respiration and Oxidative Phosphorylation in Mycobacteria
Cook, G. M., Hards, K., Vilchèze, C., Hartman, T., & Berney, M. (2014) · Microbiology Spectrum · doi:10.1128/microbiolspec.mgm2-0015-2013 · Cited by 212 · cited 1×
“tuberculosis produces energy via oxidative phosphorylation.(211) The cytochrome bcc complex (also referred to as cytochrome bc1 complex) is a component of electron transport chain of M.”
BackgroundMmpL Genes Are Associated with Mycolic Acid Metabolism in Mycobacteria and Corynebacteria
Varela, C., Rittmann, D., Singh, A., Krumbach, K., Bhatt, K., Eggeling, L., Besra, G. S., & Bhatt, A. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.03.006 · Cited by 210 · cited 1×
“MmpL3 protein is involved in this export process.(190)”
BackgroundThe F 1 F o -ATP Synthase of Mycobacterium smegmatis Is Essential for Growth
Tran, S. L., & Cook, G. M. (2005) · Journal of Bacteriology · doi:10.1128/jb.187.14.5023-5028.2005 · Cited by 116
Cited by
Gorlenko, C. L., Kiselev, H. Y., Budanova, E. V., Zamyatnin, A. A., & Ikryannikova, L. N. (2020) · Antibiotics · doi:10.3390/antibiotics9040170 · Cited by 264
Metadata
- Authors
- Bahuguna, A., & Rawat, D. S.
- Venue
- Medicinal Research Reviews
- Publisher
- Wiley
- Published
- 2019-06-28
- Volume
- 40
- Issue
- 1
- Pages
- 263-292
- ISSN
- 0198-6325 (ISSN-L)
- 1098-1128
- OpenAlex
- W2955148412
- Cited by
- 170
- References
- 13
- FWCI
- 14.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.